Free Trial

MediWound (MDWD) Stock Price, News & Analysis

-0.54 (-3.57%)
(As of 06/18/2024 ET)
Today's Range
50-Day Range
52-Week Range
44,560 shs
Average Volume
49,769 shs
Market Capitalization
$135.40 million
P/E Ratio
Dividend Yield
Price Target

MediWound MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
119.3% Upside
$32.00 Price Target
Short Interest
3.73% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.85 out of 5 stars

Medical Sector

686th out of 906 stocks

Medicinals & Botanicals Industry

5th out of 10 stocks

MDWD stock logo

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

MDWD Stock News Headlines

Buy this small stock before coming AI Tidal Wave
The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.
MediWound Ltd
MediWound Q1 2024 Earnings Preview
Buy this small stock before coming AI Tidal Wave
The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.
MediWound: Q4 Earnings Snapshot
MediWound Q4 2023 Earnings Preview
MediWound Shares Climb on Positive Data for EscharEx
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$18.69 million
Book Value
$3.43 per share


Free Float
Market Cap
$135.40 million

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Ofer Gonen B.Sc. (Age 51)
    Chief Executive Officer
    Comp: $649k
  • Ms. Hani Luxenburg (Age 51)
    Chief Financial Officer
    Comp: $235k
  • Mr. Yaron Meyer Adv. (Age 45)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $299k
  • Dr. Ety Klinger MBA (Age 62)
    Ph.D., Chief Research & Development Officer
    Comp: $377k
  • Dr. Lior Rosenberg M.D. (Age 78)
    Comp: $727k
  • Dr. Shmulik Hess Ph.D. (Age 51)
    COO & Chief Commercial Officer
  • Mr. Barry J. Wolfenson (Age 57)
    Executive Vice President of Strategy & Corporate Development
  • Dr. Robert J. Snyder CWS (Age 74)
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer

MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price target for 2024?

2 Wall Street analysts have issued twelve-month price targets for MediWound's stock. Their MDWD share price targets range from $28.00 to $36.00. On average, they expect the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 119.3% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2024?

MediWound's stock was trading at $10.17 at the beginning of the year. Since then, MDWD shares have increased by 43.5% and is now trading at $14.59.
View the best growth stocks for 2024 here

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024.
View our MDWD earnings forecast

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.04. The biopharmaceutical company earned $5.34 million during the quarter, compared to analysts' expectations of $5.33 million. MediWound had a negative trailing twelve-month return on equity of 21.67% and a negative net margin of 64.24%.

When did MediWound's stock split?

MediWound's stock reverse split on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

Who are MediWound's major shareholders?

MediWound's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (5.12%), Essex Investment Management Co. LLC (1.40%), Silverberg Bernstein Capital Management LLC (0.90%) and Janney Montgomery Scott LLC (0.32%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 6/19/2024 by Staff

From Our Partners